Black Diamond ended the second quarter of 2025 with approximately $142.8 million in cash, cash equivalents and investments, which the Company believes is sufficient to fund its anticipated operating expenses and capital expenditure requirements into the fourth quarter of 2027.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BDTX:
- Black Diamond, Nike, Apple, Block, IonQ: Trending by Analysts
- Optimistic Buy Rating for Black Diamond Therapeutics: Promising BDTX-1535 Drug and Strong Financial Position
- Black Diamond Therapeutics resumed with an Outperform at Raymond James
- Black Diamond’s 2025 Annual Stockholders Meeting Highlights